{"protocolSection":{"identificationModule":{"nctId":"NCT02598388","orgStudyIdInfo":{"id":"CR108062"},"secondaryIdInfos":[{"id":"VAC52150EBL2003","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","officialTitle":"A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-12-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-12-12","type":"ACTUAL"},"completionDateStruct":{"date":"2018-12-12","type":"ACTUAL"},"studyFirstSubmitDate":"2015-11-04","studyFirstSubmitQcDate":"2015-11-04","studyFirstPostDateStruct":{"date":"2015-11-05","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-12-10","resultsFirstSubmitQcDate":"2022-01-27","resultsFirstPostDateStruct":{"date":"2022-02-18","type":"ACTUAL"},"dispFirstSubmitDate":"2019-12-11","dispFirstSubmitQcDate":"2019-12-11","dispFirstPostDateStruct":{"date":"2019-12-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-31","lastUpdatePostDateStruct":{"date":"2025-02-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"collaborators":[{"name":"Walter Reed Army Institute of Research (WRAIR)","class":"FED"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and in HIV-infected adults.","detailedDescription":"This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, 2-part, Phase 2 study of Ad26.ZEBOV and MVA-BN-Filo in healthy and HIV infected adults. In part 1, dose 1 vaccination with MVA-Bn-Filo will be followed by dose 2 vaccination with Ad26 14 days later in the US. In part 2, two regimens will be investigated. The first regimen will be Ad26 dose 1 vaccination followed by MVA-BN-Filo dose 2, 28 days later and the second regimen will be MVA-BN-Filo dose 1 vaccination followed by Ad26.ZEBOV dose 2, 14 days later in Africa. The study consists of a Screening phase of up to 8 weeks (starting from the moment the participants signs the ICF), a Vaccination Phase, in which participants will be vaccinated at baseline (Day 1) followed by a dose 2 vaccination on Day 15 or 29, and a post-dose 2 follow-up phase of maximum 1 year post-dose 2 vaccination. Upon completion of 6-month post dose 2 visit those participants who received active vaccine will enter long-term follow-up until the 1 year post dose 2 vaccination visit to assess long-term safety and immunogenicity."},"conditionsModule":{"conditions":["Hemorrhagic Fever, Ebola"],"keywords":["Healthy","Vaccine","Ebola viruses","Ebola virus disease (EVD)","Filoviruses","Hemorrhagic fever","Monovalent vaccine","Human adenovirus serotype 26 (Ad26) encoding the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)","Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector","Safety","Immunogenicity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":578,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1 (US Participants)","type":"EXPERIMENTAL","description":"Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]},{"label":"Part 2 Group 1 (African Participants)","type":"EXPERIMENTAL","description":"Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]},{"label":"Part 2 Group 2 (African Participants)","type":"EXPERIMENTAL","description":"Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.ZEBOV","description":"One 0.5 mL intramuscular (IM) injection of (5x10\\*10 viral particles).","armGroupLabels":["Part 1 (US Participants)","Part 2 Group 1 (African Participants)","Part 2 Group 2 (African Participants)"]},{"type":"BIOLOGICAL","name":"MVA-BN-Filo","description":"One 0.5 mL IM injection of (1x10\\*8 infectious units).","armGroupLabels":["Part 1 (US Participants)","Part 2 Group 1 (African Participants)","Part 2 Group 2 (African Participants)"]},{"type":"BIOLOGICAL","name":"Placebo","description":"One 0.5 mL IM injection of 0.9 percent (%) saline.","armGroupLabels":["Part 1 (US Participants)","Part 2 Group 1 (African Participants)","Part 2 Group 2 (African Participants)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"Up to 28 days post each dose (up to Day 43)"},{"measure":"Part 2 (Group 1): Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","timeFrame":"Up to 28 days post dose 2 visit (up to Day 57)"},{"measure":"Part 1, Part 2 (Group 2): Number of Participants With Serious Adverse Events (SAEs)","description":"A SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"Up to 1 year post dose 2 (up to Day 380)"},{"measure":"Part 2 (Group 1): Number of Participants With SAEs","description":"A SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"Up to 1 year post dose 2 (up to Day 394)"},{"measure":"Part 1, Part 2 (Group 2): Number of Participants With Immediate Reportable Events (IREs)","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","timeFrame":"Up to 1 year post dose 2 (up to Day 380)"},{"measure":"Part 2 (Group 1): Number of Participants With IREs","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","timeFrame":"Up to 1 year post dose 2 (up to Day 394)"},{"measure":"Parts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) 7 Days Post First Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"7 days post dose 1 (up to Day 8)"},{"measure":"Part 1, Part 2 (Group 2): Number of Participants With Solicited Local AEs 7 Days Post Second Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post second vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"7 days post dose 2 (up to Day 22)"},{"measure":"Part 2 (Group 1): Number of Participants With Solicited Local AEs 7 Days Post Second Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post second vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"7 days post dose 2 (up to Day 36)"},{"measure":"Parts 1 and 2: Number of Participants With Solicited Systemic Adverse Events 7 Days Post First Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"7 days post dose 1 (up to Day 8)"},{"measure":"Part 1, Part 2 (Group 2): Number of Participants With Solicited Systemic AEs 7 Days Post Second Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"7 days post dose 2 (up to Day 22)"},{"measure":"Part 2 (Group 1): Number of Participants With Solicited Systemic AEs 7 Days Post Second Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"7 days post dose 2 (up to Day 36)"},{"measure":"Part 1, Part 2 (Group 2): Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. A sample was considered positive, if the value was above the lower limit of quantification (LLOQ), that is, 36.11 ELISA units/mL. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","timeFrame":"21-days post dose 2 (up to Day 36)"},{"measure":"Part 2 (Group 1): GMCs of Binding Antibody Levels Against EBOV GP Measured Using FANG ELISA","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. A sample was considered positive, if the value was above the LLOQ, that is, 36.11 ELISA units/mL.","timeFrame":"21-days post dose 2 (Day 50)"}],"secondaryOutcomes":[{"measure":"Number of Participants With Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts. This outcome measure was planned to compare the safety (unsolicited AEs, solicited local and solicited systemic AEs) of Ad26.ZEBOV/MVA-BN-Filo and MVA-BN-Filo/Ad26.ZEBOV regimens in healthy and HIV-infected participants. Therefore, placebo arm is not reported.","timeFrame":"Solicited AEs: Up to 7 days post each vaccination (Up to Day 36); Unsolicited AEs: Up to 28 days post each vaccination (Up to Day 57)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination and vital signs performed at Screening\n* Participant must be healthy on the basis of clinical laboratory tests and electrocardiogram (ECG) (only in participants \\>50 years) performed at Screening. If the results of the laboratory screening tests and ECG are outside the institutional normal reference ranges, the participant may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study\n* A woman of childbearing potential must have a negative urine β-human chorionic gonadotropin \\[beta-hCG\\] pregnancy test at Screening and a negative urine \\[beta-hCG\\] pregnancy test immediately prior to each study vaccine administration\n* A man who is sexually active with a woman of childbearing potential must be willing to use condoms for sexual intercourse beginning prior to dose 1 vaccination until at least 3 months after the dose 2 vaccination, unless a vasectomy was performed more than 1 year prior to Screening\n* Participant must pass the test of understanding (TOU)\n* Additional Inclusion Criteria for HIV-infected participants a) participants must have a positive HIV-1 and/or -2 serology test within 6 months of screening, including the day of screening; b) participants must have a Screening CD4+ cell count \\>200 cells/microliter (mcL); c) in part 1, all participants must be on a stable highly active antiretroviral therapy (HAART) regimen for 4 weeks prior to Screening, in part 2 participants with screening CD4+ cell count \\<350 cells/mcL must also be on a stable HAART regimen for 4 weeks prior to Screening\n\nExclusion Criteria:\n\n* Has received any candidate Ebola vaccine\n* Diagnosed with Ebola virus disease, or prior exposure to EBOV, including travel to epidemic Ebola areas less than 1 month prior to Screening\n* Has received any experimental candidate Ad26- or MVA-based vaccine in the past or received any other investigational drug or investigational vaccine or used an invasive investigational medical device within 3 months prior to Screening\n* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products\n* Presence of significant conditions (eg, history of seizure disorders, (auto)immune disease or deficiency, any spleen disease, active malignancy, ongoing tuberculosis treatment, other systemic infections) or clinically significant findings during screening of medical history, ECG (only in participants \\>50 years), physical examination, vital signs or laboratory testing for which, in the opinion of the investigator, participation would not be in the best interest of the participants (eg, compromise the safety or well-being) or that could prevent, limit, or confound the protocol-specified assessments","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Silver Spring","state":"Maryland","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"city":"Kericho","country":"Kenya","geoPoint":{"lat":-0.36774,"lon":35.28314}},{"city":"Kisumu","country":"Kenya","geoPoint":{"lat":-0.10221,"lon":34.76171}},{"city":"Maputo","country":"Mozambique","geoPoint":{"lat":-25.96553,"lon":32.58322}},{"city":"Abuja","country":"Nigeria","geoPoint":{"lat":9.05785,"lon":7.49508}},{"city":"Mbeya","country":"Tanzania","geoPoint":{"lat":-8.9,"lon":33.45}},{"city":"Kampala","country":"Uganda","geoPoint":{"lat":0.31628,"lon":32.58219}}]},"referencesModule":{"references":[{"pmid":"38793748","type":"DERIVED","citation":"Ake JA, Paolino K, Hutter JN, Cicatelli SB, Eller LA, Eller MA, Costanzo MC, Paquin-Proulx D, Robb ML, Tran CL, Anova L, Jagodzinski LL, Ward LA, Kilgore N, Rusnak J, Bounds C, Badorrek CS, Hooper JW, Kwilas SA, Ilsbroux I, Anumendem DN, Gaddah A, Shukarev G, Bockstal V, Luhn K, Douoguih M, Robinson C. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial. Vaccines (Basel). 2024 May 4;12(5):497. doi: 10.3390/vaccines12050497."},{"pmid":"38657084","type":"DERIVED","citation":"Mwesigwa B, Sawe F, Oyieko J, Mwakisisile J, Viegas E, Akintunde GA, Kosgei J, Kokogho A, Ntinginya N, Jani I, Shukarev G, Hooper JW, Kwilas SA, Ward LA, Rusnak J, Bounds C, Overman R, Badorrek CS, Eller LA, Eller MA, Polyak CS, Moodley A, Tran CL, Costanzo MC, Leggat DJ, Paquin-Proulx D, Naluyima P, Anumendem DN, Gaddah A, Luhn K, Hendriks J, McLean C, Douoguih M, Kibuuka H, Robb ML, Robinson C, Ake JA. Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa. Clin Infect Dis. 2024 Oct 15;79(4):888-900. doi: 10.1093/cid/ciae215."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Out of 578 randomized participants, 574 received at least one dose of study vaccine.","groups":[{"id":"FG000","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an intramuscular (IM) injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"FG001","title":"Part 1: Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"FG002","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"Human immunodeficiency virus (HIV) infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"FG003","title":"Part 1: Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"FG004","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"FG005","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"FG006","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"FG007","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"FG008","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"FG009","title":"Part 2 (Group 2): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"FG010","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"FG011","title":"Part 2 (Group 2): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"161"},{"groupId":"FG005","numSubjects":"39"},{"groupId":"FG006","numSubjects":"161"},{"groupId":"FG007","numSubjects":"39"},{"groupId":"FG008","numSubjects":"39"},{"groupId":"FG009","numSubjects":"10"},{"groupId":"FG010","numSubjects":"40"},{"groupId":"FG011","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"151"},{"groupId":"FG005","numSubjects":"38"},{"groupId":"FG006","numSubjects":"156"},{"groupId":"FG007","numSubjects":"38"},{"groupId":"FG008","numSubjects":"39"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"39"},{"groupId":"FG011","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an intramuscular (IM) injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"BG001","title":"Part 1: Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"BG002","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"Human immunodeficiency virus (HIV) infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"BG003","title":"Part 1: Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"BG004","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"BG005","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"BG006","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"BG007","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"BG008","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"BG009","title":"Part 2 (Group 2): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"BG010","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"BG011","title":"Part 2 (Group 2): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15."},{"id":"BG012","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"161"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"161"},{"groupId":"BG007","value":"39"},{"groupId":"BG008","value":"39"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"40"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"574"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42","spread":"14.42"},{"groupId":"BG001","value":"47.3","spread":"11.84"},{"groupId":"BG002","value":"46.7","spread":"12.89"},{"groupId":"BG003","value":"46","spread":"8.63"},{"groupId":"BG004","value":"29.1","spread":"7.56"},{"groupId":"BG005","value":"28.4","spread":"7.37"},{"groupId":"BG006","value":"37.5","spread":"9.78"},{"groupId":"BG007","value":"38.9","spread":"8.74"},{"groupId":"BG008","value":"28","spread":"7.72"},{"groupId":"BG009","value":"26.9","spread":"12.56"},{"groupId":"BG010","value":"38.5","spread":"9.91"},{"groupId":"BG011","value":"41","spread":"9.78"},{"groupId":"BG012","value":"34.8","spread":"11.02"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"69"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"95"},{"groupId":"BG007","value":"22"},{"groupId":"BG008","value":"20"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"26"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"289"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"92"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"66"},{"groupId":"BG007","value":"17"},{"groupId":"BG008","value":"19"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"14"},{"groupId":"BG011","value":"6"},{"groupId":"BG012","value":"285"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"20"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"154"},{"groupId":"BG005","value":"38"},{"groupId":"BG006","value":"158"},{"groupId":"BG007","value":"37"},{"groupId":"BG008","value":"38"},{"groupId":"BG009","value":"9"},{"groupId":"BG010","value":"40"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"554"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"160"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"159"},{"groupId":"BG007","value":"39"},{"groupId":"BG008","value":"39"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"40"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"538"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"34"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"KENYA","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"79"},{"groupId":"BG007","value":"21"},{"groupId":"BG008","value":"10"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"15"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"197"}]}]},{"title":"MOZAMBIQUE","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"23"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"83"}]}]},{"title":"NIGERIA","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"38"}]}]},{"title":"TANZANIA, UNITED REPUBLIC OF","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"75"}]}]},{"title":"UGANDA","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"34"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"106"}]}]},{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"75"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on full analysis set (FAS) which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post each dose (up to Day 43)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Human immunodeficiency virus (HIV)- infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post dose 2 visit (up to Day 57)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"15"}]}]}]},{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Number of Participants With Serious Adverse Events (SAEs)","description":"A SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 1 year post dose 2 (up to Day 380)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): Number of Participants With SAEs","description":"A SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 1 year post dose 2 (up to Day 394)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Number of Participants With Immediate Reportable Events (IREs)","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 1 year post dose 2 (up to Day 380)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): Number of Participants With IREs","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 1 year post dose 2 (up to Day 394)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Parts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) 7 Days Post First Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 1 (up to Day 8)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG004","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG005","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG006","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG007","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"161"},{"groupId":"OG005","value":"39"},{"groupId":"OG006","value":"161"},{"groupId":"OG007","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"71"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"75"},{"groupId":"OG007","value":"7"}]}]}]},{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Number of Participants With Solicited Local AEs 7 Days Post Second Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post second vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 2 (up to Day 22)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): Number of Participants With Solicited Local AEs 7 Days Post Second Vaccination","description":"Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post second vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 2 (up to Day 36)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"160"},{"groupId":"OG003","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"7"}]}]}]},{"type":"PRIMARY","title":"Parts 1 and 2: Number of Participants With Solicited Systemic Adverse Events 7 Days Post First Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 1 (up to Day 8)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG004","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG005","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG006","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG007","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"161"},{"groupId":"OG005","value":"39"},{"groupId":"OG006","value":"161"},{"groupId":"OG007","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"109"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"97"},{"groupId":"OG007","value":"18"}]}]}]},{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Number of Participants With Solicited Systemic AEs 7 Days Post Second Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 2 (up to Day 22)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"4"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): Number of Participants With Solicited Systemic AEs 7 Days Post Second Vaccination","description":"Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post dose 2 (up to Day 36)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"160"},{"groupId":"OG003","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"10"}]}]}]},{"type":"PRIMARY","title":"Part 1, Part 2 (Group 2): Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. A sample was considered positive, if the value was above the lower limit of quantification (LLOQ), that is, 36.11 ELISA units/mL. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts.","populationDescription":"The per protocol analysis set included all randomized and vaccinated participants, who received both the dose 1 and dose 2 vaccinations (administered within the protocol-defined visit window), had at least 1 post-vaccination (that is, after the date of vaccination) evaluable immunogenicity sample, and had no major protocol violations influencing the immune responses. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"21-days post dose 2 (up to Day 36)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG001","title":"Healthy (Part 1, Part 2; Group 2): Placebo","description":"Healthy participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."},{"id":"OG002","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo (Dose 1) on Day 1 followed by IM injection of single dose Ad26.ZEBOV (Dose 2) at Day 15."},{"id":"OG003","title":"HIV-infected (Part 1, Part 2; Group 2): Placebo","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose placebo (Dose 1) on Day 1 followed by IM injection of single dose placebo (Dose 2) at Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5733","lowerLimit":"4245","upperLimit":"7742"},{"groupId":"OG001","value":"40","lowerLimit":"NA","upperLimit":"112","comment":"Here, 'NA' signifies that lower limit of calculated 95% CI was less than LLOQ."},{"groupId":"OG002","value":"2325","lowerLimit":"1632","upperLimit":"3313"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"38","comment":"Here, 'NA' signifies that geometric mean and lower limit of calculated 95% CI was less than LLOQ."}]}]}]},{"type":"PRIMARY","title":"Part 2 (Group 1): GMCs of Binding Antibody Levels Against EBOV GP Measured Using FANG ELISA","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. A sample was considered positive, if the value was above the LLOQ, that is, 36.11 ELISA units/mL.","populationDescription":"The per protocol analysis set included all randomized and vaccinated participants, who received both the dose 1 and dose 2 vaccinations (administered within the protocol-defined visit window), had at least 1 post-vaccination (that is, after the date of vaccination) evaluable immunogenicity sample, and had no major protocol violations influencing the immune responses. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"21-days post dose 2 (Day 50)","groups":[{"id":"OG000","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG001","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"155"},{"groupId":"OG003","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6037","lowerLimit":"4996","upperLimit":"7297"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that calculated Geometric mean and the limits of the 95% CI were less than LLOQ"},{"groupId":"OG002","value":"2939","lowerLimit":"2316","upperLimit":"3729"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that calculated Geometric mean and the limits of the 95% CI were less than LLOQ"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. As per planned analysis, the data from Parts 1 and 2 (Group 2) of the study was pooled (that is, 14-day interval regimen) and presented separately for the healthy and HIV-infected cohorts. This outcome measure was planned to compare the safety (unsolicited AEs, solicited local and solicited systemic AEs) of Ad26.ZEBOV/MVA-BN-Filo and MVA-BN-Filo/Ad26.ZEBOV regimens in healthy and HIV-infected participants. Therefore, placebo arm is not reported.","populationDescription":"Safety set was based on FAS which included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Solicited AEs: Up to 7 days post each vaccination (Up to Day 36); Unsolicited AEs: Up to 28 days post each vaccination (Up to Day 57)","groups":[{"id":"OG000","title":"Healthy (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"Healthy participants in Part 1 and Part 2 (Group 2) received intramuscular (IM) injection of single dose MVA-BN-Filo as prime vaccine on Day 1 followed by IM injection of single dose Ad26.ZEBOV as booster vaccine at Day 15."},{"id":"OG001","title":"HIV-infected (Part 1, Part 2; Group 2): MVA-BN-Filo and Ad26.ZEBOV","description":"HIV-infected participants in Part 1 and Part 2 (Group 2) received IM injection of single dose MVA-BN-Filo as prime vaccine on Day 1 followed by IM injection of single dose Ad26.ZEBOV as booster vaccine at Day 15."},{"id":"OG002","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."},{"id":"OG003","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"161"}]}],"classes":[{"title":"Unsolicited AEs","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"83"},{"groupId":"OG003","value":"78"}]}]},{"title":"Solicited Local AEs","categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"103"},{"groupId":"OG003","value":"93"}]}]},{"title":"Solicited Systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"116"},{"groupId":"OG003","value":"117"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Day 380 (Part 1, Part 2; Group 2) and Up to Day 394 (Part 2; Group 1)","description":"Safety set included all participants who were randomized and received at least 1 dose of study vaccine, regardless of the occurrence of protocol deviations.","eventGroups":[{"id":"EG000","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an intramuscular (IM) injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":40,"seriousNumAffected":1,"seriousNumAtRisk":40,"otherNumAffected":11,"otherNumAtRisk":40},{"id":"EG001","title":"Part 1: Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG002","title":"Part 1: MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"Human immunodeficiency virus (HIV) infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":11,"otherNumAtRisk":20},{"id":"EG003","title":"Part 1: Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":1,"seriousNumAtRisk":5,"otherNumAffected":0,"otherNumAtRisk":5},{"id":"EG004","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":39,"seriousNumAffected":0,"seriousNumAtRisk":39,"otherNumAffected":12,"otherNumAtRisk":39},{"id":"EG005","title":"Part 2 (Group 2): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG006","title":"Part 2 (Group 2): MVA-BN-Filo and Ad26.ZEBOV (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose MVA-BN-Filo (Dose 1) at Day 1 followed by an IM injection of a single dose Ad26.ZEBOV (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":40,"seriousNumAffected":2,"seriousNumAtRisk":40,"otherNumAffected":13,"otherNumAtRisk":40},{"id":"EG007","title":"Part 2 (Group 2): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 15.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":3,"otherNumAtRisk":10},{"id":"EG008","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29.","deathsNumAffected":0,"deathsNumAtRisk":161,"seriousNumAffected":1,"seriousNumAtRisk":161,"otherNumAffected":53,"otherNumAtRisk":161},{"id":"EG009","title":"Part 2 (Group 1): Placebo (Healthy Participants)","description":"Healthy participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29.","deathsNumAffected":0,"deathsNumAtRisk":39,"seriousNumAffected":1,"seriousNumAtRisk":39,"otherNumAffected":15,"otherNumAtRisk":39},{"id":"EG010","title":"Part 2 (Group 1): Ad26.ZEBOV and MVA-BN-Filo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose Ad26.ZEBOV (Dose 1) at Day 1 followed by an IM injection of a single dose MVA-BN-Filo (Dose 2) at Day 29.","deathsNumAffected":0,"deathsNumAtRisk":161,"seriousNumAffected":2,"seriousNumAtRisk":161,"otherNumAffected":51,"otherNumAtRisk":161},{"id":"EG011","title":"Part 2 (Group 1): Placebo (HIV-infected Participants)","description":"HIV-infected participants received an IM injection of a single dose placebo (Dose 1) at Day 1 followed by an IM injection of a single dose placebo (Dose 2) at Day 29.","deathsNumAffected":0,"deathsNumAtRisk":39,"seriousNumAffected":0,"seriousNumAtRisk":39,"otherNumAffected":11,"otherNumAtRisk":39}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Peptic Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Anaphylactic Reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Appendicitis Perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":1,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Postoperative Wound Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":1,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Staphylococcal Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":1,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Typhoid Fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Soft Tissue Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Cervical Cord Compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":1,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Panic Attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":3,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":3,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":1,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":3,"numAtRisk":161},{"groupId":"EG009","numAffected":2,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":3,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":2,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Dental Caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":2,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":2,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":3,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":4,"numAtRisk":39}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":2,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Injection Site Erosion","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Body Tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":3,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":2,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":3,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":4,"numAtRisk":39},{"groupId":"EG005","numAffected":2,"numAtRisk":10},{"groupId":"EG006","numAffected":2,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":5,"numAtRisk":161},{"groupId":"EG009","numAffected":1,"numAtRisk":39},{"groupId":"EG010","numAffected":5,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Otitis Media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":2,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":2,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":4,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Rash Pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":2,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":1,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":1,"numAtRisk":39},{"groupId":"EG010","numAffected":3,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":5,"numAtRisk":39},{"groupId":"EG005","numAffected":3,"numAtRisk":10},{"groupId":"EG006","numAffected":3,"numAtRisk":40},{"groupId":"EG007","numAffected":3,"numAtRisk":10},{"groupId":"EG008","numAffected":23,"numAtRisk":161},{"groupId":"EG009","numAffected":4,"numAtRisk":39},{"groupId":"EG010","numAffected":25,"numAtRisk":161},{"groupId":"EG011","numAffected":5,"numAtRisk":39}]},{"term":"Apheresis Related Complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Meniscus Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Muscle Strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Procedural Pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Soft Tissue Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":1,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":1,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":3,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":1,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":1,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":2,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":3,"numAtRisk":39},{"groupId":"EG010","numAffected":4,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":4,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":9,"numAtRisk":161},{"groupId":"EG009","numAffected":3,"numAtRisk":39},{"groupId":"EG010","numAffected":9,"numAtRisk":161},{"groupId":"EG011","numAffected":1,"numAtRisk":39}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":2,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":2,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":2,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Rhinitis Allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":0,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":1,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":20},{"groupId":"EG003","numAffected":0,"numAtRisk":5},{"groupId":"EG004","numAffected":0,"numAtRisk":39},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":40},{"groupId":"EG007","numAffected":0,"numAtRisk":10},{"groupId":"EG008","numAffected":1,"numAtRisk":161},{"groupId":"EG009","numAffected":0,"numAtRisk":39},{"groupId":"EG010","numAffected":0,"numAtRisk":161},{"groupId":"EG011","numAffected":0,"numAtRisk":39}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"MEDICAL LEADER","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-09-18","uploadDate":"2021-12-10T07:37","filename":"Prot_000.pdf","size":1639693},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-04-16","uploadDate":"2021-12-10T07:37","filename":"SAP_001.pdf","size":1024344}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D019142","term":"Hemorrhagic Fever, Ebola"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}],"ancestors":[{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D018702","term":"Filoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"}]}},"hasResults":true}